Abu Dhabi's Mubadala invests $250mln in biosimulation firm Certara

The transaction is scheduled to close on August 2, 2021

  
A view of Mubadala Building in Abu Dhabi. Image used for illustrative purpose

A view of Mubadala Building in Abu Dhabi. Image used for illustrative purpose

Mubadala/ Handout via Zawya

Abu Dhabi’s Mubadala Investment Company has made an investment worth approximately $250 million in Certara, a Nasdaq-listed biosimulation company.

Mubadala and certain existing institutional shareholders of Certara, including a shareholder affiliated with EQT, a private equity company, have entered into an agreement under which an affiliate of Mubadala will purchase an aggregate of 9,615,384 shares at $26 per share from the shareholders in a private transaction.

The transaction is scheduled to close on August 2, 2021. EQT will remain a significant shareholder in the company after the transaction, Mubadala said in a statement Wednesday.

The sovereign investor, which manages a global portfolio of $232 billion aimed at generating sustainable financial returns for the Government of Abu Dhabi, said this investment aligned with its strategy of “enabling innovation to address unmet clinical needs and drive cost efficiencies.”

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies.

Camilla Languille, Head of Life Sciences at Mubadala, said, “Biosimulation is transforming traditional drug development via computational approaches that save time and cost throughout the entire biopharma R&D process. We are proud to have invested in Certara, whose market-leading software is accelerating the development of new medicines that improve the lives of patients.”

(Writing by Brinda Darasha; editing by Seban Scaria)

brinda.darasha@refinitiv.com

This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Read our full disclaimer policy here.  

© ZAWYA 2021

More From Wealth Management